​NAYA is pioneering the next generation of cancer therapies by harnessing the transformational potential of two synergistic modalities - astatine-211 (²¹¹At) targeted alpha therapies & bifunctional antibodies - to unlock deeper, more durable responses in patients not responding to current standard-of-care. ​​​​​​​​
Flex-NK™
Bifunctional Antibodies
Our initial strategic focus for both modalities is on hepatocellular carcinoma (HCC) – an indication with over a million new cases annually, rapidly-growing incidence, and a lack of safe and effective therapeutic options for the majority of patients not responding to treatment.
​Livers afflicted with HCC are highly-challenging environments for therapeutics due to their critical function, delicate physiology, and often already impaired-status. This means even minimal toxicity or collateral damage within the liver can risk life-threatening organ failure.​​​
​​The distinct characteristics of both of our modalities, including enhanced safety, precision, and alignment with the liver's biology, make NY-703 & NY-303 ideally-suited to address the challenges of targeting HCC in the liver. ​